Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes

Saved in:
Bibliographic Details
Published inLeukemia & lymphoma Vol. 58; no. 9; pp. 2264 - 2267
Main Authors Bohl, Stephan R., Dolnik, Anna, Jensen, Thomas, Lang, Katharina M., Hackanson, Björn, Gaidzik, Verena I., Paschka, Peter, Knudsen, Steen, Döhner, Konstanze, Döhner, Hartmut, Claus, Rainer, Lübbert, Michael, Bullinger, Lars
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 02.09.2017
Subjects
Antimetabolites, Antineoplastic - administration & dosage
Antimetabolites, Antineoplastic - adverse effects
Antimetabolites, Antineoplastic - therapeutic use
Azacitidine - administration & dosage
Azacitidine - adverse effects
Azacitidine - analogs & derivatives
Azacitidine - therapeutic use
Biomarkers, Tumor
Decitabine
Gene Expression Profiling
Gene Expression Regulation, Leukemic
Genes, Tumor Suppressor
Humans
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - genetics
Leukemia, Myeloid, Acute - mortality
Leukemia, Myeloid, Acute - pathology
Transcriptome
Treatment Outcome
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1042-8194
1029-2403
DOI:10.1080/10428194.2017.1287360